Benzinga | Aug 19, 2021 09:20AM EDT

UBS Initiates Coverage On Ultragenyx Pharmaceutical with Sell Rating, Announces Price Target of $73

UBS analyst Esther Rajavelu initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Sell rating and announces Price Target of $73.